AstraZeneca lines up a $20M installment plan to launch a new oncology collaboration with microbiome player Seres

AstraZeneca has set up a research deal with Seres Therapeutics, agreeing to pay the biotech $20 million in installment payments for their collaboration on exploring how the gut can influence the efficacy of immuno-oncology drugs like their PD-L1 Imfinzi.